The FDA has approved a new Alzheimer's drug. I mentioned it before on my show with great interest because my dad suffers from the disease: Donanemab was the drug I talked about.. The new treatment by Eli Lilly will be sold under the brand name Kisunla, and was approved Tuesday by the FDA after outside experts said the benefits of the drug outweighed its risks. The drug is designed to clear the brain of an Alzheimer's-related protein called beta amyloid. In a late-stage trial, the drug slowed the progression of memory problems by 29% compared with a placebo.
BUT HERE'S THE BAD NEWS:
Lilly is charging about 700-dollars a vial for the drug, or 32-thousand dollars for a 12-month treatment.